Global Custom Market Research Reports Provider Company

phone

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 58
  • Category: Pharmaceuticals
  • Country: Global

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H1 2018

Summary

According to the recently published report Neutrophil Elastase - Pipeline Review, H1 2018; Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Neutrophil elastase is a serine proteinase. It is secreted from neutrophils. It is involved in inflammatory diseases, including idiopathic pulmonary fibrosis, rheumatoid arthritis, adult respiratory distress syndrome, and cystic fibrosis. It modifies the functions of natural killer cells, monocytes and granulocytes. It inhibits C5a-dependent neutrophil enzyme release and chemotaxis.

The report Neutrophil Elastase - Pipeline Review, H1 2018 outlays comprehensive information on the Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Respiratory, Immunology, Central Nervous System, Oncology, Cardiovascular, Genetic Disorders, Hematological Disorders, Infectious Disease, Metabolic Disorders and Toxicology which include indications Cystic Fibrosis, Inflammation, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alpha- Antitrypsin Deficiency, Bronchiectasis, Bronchiolitis Obliterans, Chemotherapy Effects, Ischemia Reperfusion Injury, Lung Disease, Lung Injury, Lung Transplant Rejection, Myelodysplastic Syndrome, Neuromyelitis Optica (Devic’s Syndrome), Neutropenia, Primary Ciliary Dyskinesia, Pulmonary Arterial Hypertension, Thrombocytopenia, Traumatic Brain Injury, Type 2 Diabetes and Vascular Injury.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
- The report reviews Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  

Publisher Name : Global Markets Direct


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Overview
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Cantex Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Kyorin Pharmaceutical Co Ltd
Polyphor Ltd
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Drug Profiles
alvelestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANV-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHF-6333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KRP-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-6014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sivelestat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Neutrophil Elastase for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Neutrophil Elastase for Lung Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tiprelestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Dormant Products
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Discontinued Products
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
Jun 06, 2016: Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis
Jun 06, 2016: Proteo receives US$ 1 million grant for a new Elafin drug formulation
Mar 23, 2016: Polyphor announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014
Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I
Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs
Nov 21, 2014: Final Analysis of the Phase II Clinical Study on Elafin in coronary artery bypass surgery completed
May 20, 2014: $ 4.8 Million Funding for Proteo’s Advanced Orphan Drug Development
Nov 08, 2013: Proteo, Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed
Mar 20, 2013: Proteos Elafin Obtains FDA Orphan Drug Designation For Prevention Of Inflammatory Complications Of Transthoracic Esophagectomy
Jan 10, 2013: Proteos Elafin Receives FDA Orphan Drug Designation For Treatment Of Pulmonary Arterial Hypertension
Dec 11, 2012: Proteo Announces Patient Recruitment For EMPIRE Study Of Elafin Surpassed Expectations
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
  



List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Cantex Pharmaceuticals Inc, H1 2018
Pipeline by Chiesi Farmaceutici SpA, H1 2018
Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Pipeline by Polyphor Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
  



List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  



The global market size of Anti-Neutrophil Cytoplasmic Antibody is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H1 2018 Summary

View Report

Neutrophil Elastase Inhibitor - Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Neutrophil Elastase Inhibitor development.

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports